12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Company News  |  Deals

Kolltan, AstraZeneca deal

Kolltan received exclusive rights to a mAb against epidermal growth factor receptor 3 ( EGFR3; HER3;...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >